<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744742</url>
  </required_header>
  <id_info>
    <org_study_id>G-CSF+Dec+BUCYvsBUCY-MDS-2016</org_study_id>
    <nct_id>NCT02744742</nct_id>
  </id_info>
  <brief_title>G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT</brief_title>
  <official_title>Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient
      tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess
      blasts-2 (RAEB-2) and acute myeloid leukemia (AML) secondary to myelodysplastic syndrome
      (MDS). At present, the best conditioning regimen for RAEB-1, RAEB-2 and AML secondary to MDS
      undergoing allo-HSCT remains in discussion. In this prospective randomized controlled study,
      the safety and efficacy of G-CSF+ Decitabine + BUCY and BUCY myeloablative conditioning
      regimens in patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT are
      evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allo-HSCT appears to be an efficient tool to cure patients with MDS and AML secondary to MDS.
      At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing
      allo-HSCT remains in discussion. BUCY conditioning regimen is the standard myeloablative
      regimen for MDS and AML secondary to MDS undergoing allo-HSCT. However, it appears to have
      higher relapse rate. To reduce the relapse rate, decitabine is added in the conditioning
      regimen. In this prospective randomized controlled study, the safety and efficacy of G-CSF +
      Decitabine + BUCY and BUCY myeloablative conditioning regimens in RAEB-1, REAB-2 and AML
      secondary to MDS undergoing allo-HSCT are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse rate</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transplant-related mortality (TRM)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <condition>Conditioning</condition>
  <arm_group>
    <arm_group_label>G-CSF + Decitabine + BUCY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUCY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine was administered at 20mg/m2/day on days -14 and -10.</description>
    <arm_group_label>G-CSF + Decitabine + BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (BU)</intervention_name>
    <description>Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.</description>
    <arm_group_label>G-CSF + Decitabine + BUCY</arm_group_label>
    <arm_group_label>BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CY)</intervention_name>
    <description>Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.</description>
    <arm_group_label>G-CSF + Decitabine + BUCY</arm_group_label>
    <arm_group_label>BUCY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony-Stimulating Factor(G-CSF)</intervention_name>
    <description>G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.</description>
    <arm_group_label>G-CSF + Decitabine + BUCY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT

          -  14-65 years

        Exclusion Criteria:

          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          -  Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifa Liu</last_name>
    <email>liuqifa628@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Xuan</last_name>
      <phone>+86-020-61641613</phone>
      <email>356135708@qq.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

